Tag results:
COVID-19
Immunology of Infectious Disease News
Live Attenuated Virus Vaccine Protects against SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha) and B.1.351 (Beta)
[Science Advances] Researchers assessed the immunogenicity and protective efficacy of sCPD9 in the Roborovski dwarf hamster, a nontransgenic rodent species that was highly susceptible to SARS-CoV-2 and severe COVID-19–like disease.
Neural Cell News
Lixte Biotechnology Holdings, Inc. Announces That Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound Lb-100 to Enter Recurrent,...
[Lixte Biotechnology Holdings, Inc.] Lixte Biotechnology Holdings, Inc. announced that the National Cancer Institute has resumed enrolling patients into their pharmacologic study of the ability of Lixte’s lead compound, LB-100, to enter the brain and penetrate recurrent, malignant brain tumors, in patients where surgical removal of their cancer is indicated.
Immunology of Infectious Disease News
Protective Activity of mRNA Vaccines against Ancestral and Variant SARS-CoV-2 Strains
[Science Translational Medicine] The authors assessed the immunogenicity and protective activity of historical or modified Moderna mRNA vaccines in 129S2 and K18-hACE2 mice.
Immunology of Infectious Disease News
Integrated Immunovirological Profiling Validates Plasma SARS-CoV-2 RNA as an Early Predictor of COVID-19 Mortality
[Science Advances] To identify early predictors of mortality within 60 days of symptom onset, researchers performed immunovirological assessments on plasma from 279 individuals.
Immunology of Infectious Disease News
A Single Dose, BCG-Adjuvanted COVID-19 Vaccine Provides Sterilising Immunity against SARS-CoV-2 Infection
[NPJ Vaccines] Scientists exploited the immunostimulatory properties of bacille Calmette-Guérin, the existing tuberculosis vaccine, to deliver a vaccination regimen with potent SARS-CoV-2-specific protective immunity.
Mesenchymal Cell News
Dual Electrochemical Sensing of Spiked Virus and SARS-CoV-2 Using Natural Bed-Receptor (MV-gal1)
[Scientific Reports] Investigators introduced a natural bed-receptor surface as Microparticle Vesicle-Galactins1 (MV-gal1) with the ability of glycan binding to screen every spiked virus.